VIPER101NCT06420089
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 22 words Show 4 more changesShow less
- Trial completed
- Final enrollment: 19 participants (planned 30)
- Primary completion date changed from estimate of Aug 30, 2028 to Sep 24, 2026
- Site details revised at 2 of 2 sites
- Notable Primary completion date: Aug 30, 2026 to Aug 30, 2028
- Study completion date: Jun 30, 2027 to Aug 30, 2029
- Minor Study sites: 1 to 2v4
- Minor Start date changed from estimate of Aug 30, 2024 to Oct 4, 2024
- Study site revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jun 30, 2024 to Aug 30, 2024
- Primary completion date: Jun 30, 2026 to Aug 30, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Determine the recommended phase 2 dose (RP2D) of Senza5 CART5 cells
Timeframe: 12 months
Secondary (4)
Determine the safety of Senza5 CART5 cells
Determine the maximum tolerated dose (MTD)
Determine the manufacturing feasibility of Senza5 CART5
Determine efficacy of Senza5 CART5
Arms and interventions
Senza5 CART5 with standard of care lymphodepletionExperimental
Four treatment arms with Standard of Care Lymphodepletion: Fludarabine 25mg/m2 IV for 3 days Cyclophosphamide 250mg/m2 IV for 3 days
Senza5 CART5 without standard of care lymphodepletionExperimental
Four treatment arms in patients are lymphopenic into the corresponding dose level.
Drugs: Senza5 CART5
Sites
2 sites in 1 country